<DOC>
	<DOCNO>NCT00002960</DOCNO>
	<brief_summary>RATIONALE : Giving p53 gene ovarian , fallopian tube , peritoneal cancer may inhibit tumor growth . Giving gene directly peritoneum may kill cancer cell . PURPOSE : Phase I trial study effectiveness SCH-58500 treating patient recurrent persistent primary ovarian , fallopian tube , peritoneal cancer .</brief_summary>
	<brief_title>SCH-58500 Treating Patients With Primary Ovarian , Fallopian Tube , Peritoneal Cancer ( C95084 )</brief_title>
	<detailed_description>OBJECTIVES : I. Assess safety SCH-58500 ( recombinant adenoviral vector contain p53 tumor suppressor gene ) give single multiple intraperitoneal instillation combination chemotherapy patient peritoneal carcinomatosis demonstrate p53 mutant ovarian , fallopian tube , peritoneal carcinoma . II . Assess biological activity SCH-58500 confirming wild type p53 gene expression . III . Assess stability SCH-58500 infection expression collection analysis serial , posttreatment , ascites specimen subset 5 patient . IV . Assess pharmacokinetics SCH-58500 serum peritoneal fluid measurement . V. Document clinical evidence antitumor activity patient treat regimen . OUTLINE : This abbreviate dose escalation , multicenter study SCH-58500 . Patients receive SCH-58500 intraperitoneal instillation day 1-5 ( depend dose level ) . Patients undergo ascites fluid tumor sample intraperitoneal instillation . The ascitic fluid tumor normal tissue submit cytologic histopathologic examination biological activity analysis . Cohorts 3-6 patient receive escalate dos SCH-58500 3 patient experience dose limit toxicity high plan dose reach . Patients follow 2 month , every 3 month 1 year , yearly thereafter . PROJECTED ACCRUAL : A total 6-60 patient accrue study .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Radiographic surgical evidence primary ovarian , fallopian tube , peritoneal carcinoma Ascites cytologically positive peritoneal carcinomatosis recurrent persistent ovarian , fallopian tube , peritoneal carcinoma Must ascites tumor accessible laparoscopic percutaneous biopsy Immunohistochemical evidence p53 gene mutation ascitic fluid cell block primary tumor biopsy document mutation PATIENT CHARACTERISTICS : Age : 18 Life expectancy : At least 3 month Performance status : Karnofsky 60100 % Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL AST/ALT le 1.5 time upper limit normal ( ULN ) Alkaline phosphatase less 1.5 time ULN Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 50 mL/min Other : Ability tolerate pair paracenteses biopsy ( percutaneous laparoscopic ) HIV negative No adenoviral infection determine ELISA screen No uncontrolled serious bacterial , viral , fungal parasitic infection No known suspect hypersensitivity study drug excipient use formulation delivery system No underlie medical condition would obscure interpretation adverse event Not pregnant nursing Fertile patient must use effective contraception least 1 month , , 6 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 month since prior biologic therapy recover Chemotherapy : At least 3 month since local intraperitoneal antitumor therapy direct peritoneal carcinomatosis recover At least 1 month since systemic chemotherapy ovarian , fallopian tube , peritoneal cancer unapproved indication recover Endocrine therapy : At least 3 month since systemic corticosteroid therapy Radiotherapy : At least 1 year since prior total abdominal radiotherapy Surgery : Not specify Other : At least 3 month since prior investigational therapy recover At least 3 month since prior immunosuppressive therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>malignant ascites</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>